Model AM-301 - Viral Infections and Allergies

Preventive use of Bentrio™ reduces SARS-CoV-2 titer by up to 99.4% and 83% for the Alpha and Delta variants, respectively.

Mean viral titer in Vero cells over four days following inoculation of human nasal epithelium model with SARS-CoV-2. Treatment with saline solution (control), AM-301 (Bentrio™) or AM-301 without key component (matrix) started 10 minutes prior to inoculation and continued once daily. Compared to the saline control group, Bentrio™ achieved a reduction in viral titer of >99% for the Alpha and 83% for the Delta variants on Days 3 and 4.

Bentrio™ reduces SARS-CoV-2 titer by up to 92% and 69-85% for the Alpha and Delta variants, respectively, when applied on an already ongoing infection (i.e. used as a treatment).

Mean viral titer in Vero cells over four days following inoculation of human nasal epithelium model with SARS-CoV-2. Treatment with saline solution (control), AM-301 (Bentrio™) or AM-301 without key component (matrix) started 24 hours after inoculation and continued once daily for 4 days. Compared to the saline control group, Bentrio™ achieved a reduction in viral titer of >92% on Day 4 for the Alpha variant and 69 and 83% on days 3 and 4, respectively, for the Delat variant.

Bentrio™ alleviates allergic rhinitis symptoms.

Mean change in the Total Nasal Symptom Score (TNSS) during stay of study participants with history of allergic rhinitis in grass pollen challenge chamber. A single dose of Bentrio™ applied into each nostril  prior to entering the chamber provided for a significant reduction in the self-rated TNSS.